Details and Advantages
Applications:
ELISA,Flow Cyt
Reactivity:
Human
Conjugate:
Unconjugated
Advantages:
High lot-to-lot consistency
Increased sensitivity and higher affinity
Animal-free production
Summary
>
Description:
Anti-IFNB1, AlpHcAbs® Human antibody is designed for detecting human IFNB1 specifically. Based on ELISA and/or FCM, Anti-IFNB1, AlpHcAbs® Human antibody reacts with human IFNB1 specifically.
Immunogen: Recombinant human IFNB1
Host: Alpaca pacous
Isotype: Human IgG1
Conjugate: Unconjugated
Specificity: Human IFNB1
Purity: Recombinant Expression and Affinity purified
Concentration: 1mg/ml
Formation: Liquid, 10mM PBS (pH 7.5), 0.05% sucrose, 0.1% trehalose, 0.01% proclin300, 50% Glycerol
Storage: Store at –20 °C, (Avoid freeze / thaw cycles)
Background:
Type I Interferons (IFN-alpha/beta) are produced primarily in response to viral infection by Natural IFN-producing cells (IPCs) as part of the host immune response. IFNs can also inhibit the development of tumors. IFN-beta binding results in the activation of the tyrosine kinases Jak1 and Tyk2, phosphorylation of members of the STAT family of transcription factors, and the transcription and expression of the immune response genes. More recently, several members of the toll-like receptor (TLR) family were found to stimulate the production IFN-beta. IFN-beta is currently used clinically for treatment of tumors, infections and multiple sclerosis.
Anti-IFNB1, AlpHcAbs® Human antibody is designed for detecting human IFNB1 specifically. Based on ELISA and/or FCM, Anti-IFNB1, AlpHcAbs® Human antibody reacts with human IFNB1 specifically.
Immunogen: Recombinant human IFNB1
Host: Alpaca pacous
Isotype: Human IgG1
Conjugate: Unconjugated
Specificity: Human IFNB1
Purity: Recombinant Expression and Affinity purified
Concentration: 1mg/ml
Formation: Liquid, 10mM PBS (pH 7.5), 0.05% sucrose, 0.1% trehalose, 0.01% proclin300, 50% Glycerol
Storage: Store at –20 °C, (Avoid freeze / thaw cycles)
Background:
Type I Interferons (IFN-alpha/beta) are produced primarily in response to viral infection by Natural IFN-producing cells (IPCs) as part of the host immune response. IFNs can also inhibit the development of tumors. IFN-beta binding results in the activation of the tyrosine kinases Jak1 and Tyk2, phosphorylation of members of the STAT family of transcription factors, and the transcription and expression of the immune response genes. More recently, several members of the toll-like receptor (TLR) family were found to stimulate the production IFN-beta. IFN-beta is currently used clinically for treatment of tumors, infections and multiple sclerosis.
Performance
>
ELISA: 1:4,000-1:10000
Flow Cytometry：1:200-1:1000
Dilution factors are presented in the form of a range because the optimal dilution is a function of many factors, such as antigen density, permeability, etc. The actual dilution used must be determined empirically.
Flow Cytometry：1:200-1:1000
Dilution factors are presented in the form of a range because the optimal dilution is a function of many factors, such as antigen density, permeability, etc. The actual dilution used must be determined empirically.
